PMID- 20332298
OWN - NLM
STAT- MEDLINE
DCOM- 20100625
LR  - 20211020
IS  - 1940-6215 (Electronic)
IS  - 1940-6207 (Print)
IS  - 1940-6215 (Linking)
VI  - 3
IP  - 4
DP  - 2010 Apr
TI  - The detection of chromosomal aneusomy by fluorescence in situ hybridization in 
      sputum predicts lung cancer incidence.
PG  - 447-53
LID - 10.1158/1940-6207.CAPR-09-0165 [doi]
AB  - Lung cancer usually is disseminated (advanced) and has a poor prognosis at 
      diagnosis. Current and former smokers are at a high risk for lung cancer and are 
      candidates for prevention and early detection strategies. Sputum is a potential 
      source of biomarkers that might determine either lung cancer risk or the presence 
      of early lung cancer, but no current sputum test is sufficiently sensitive and 
      specific for effective screening. We used fluorescence in situ hybridization 
      (FISH) to measure chromosomal aneusomy (CA) in sputum samples collected 
      prospectively from 100 incident lung cancer cases and 96 controls (matched on 
      age, gender, and date of collection) nested within an ongoing high-risk cohort. 
      The CA-FISH assay was aimed at four DNA targets: epidermal growth factor 
      receptor, MYC, 5p15, and CEP 6. The sensitivity of a positive CA-FISH assay 
      (abnormal for two or more of the four markers) for lung cancer was substantially 
      higher for samples collected within 18 months (76% sensitivity) than for samples 
      collected more than 18 months (31%) before lung cancer diagnosis. Sensitivity was 
      higher for squamous cell cancers (94%) than for other histologic types (69%). 
      CA-FISH specificity based on samples collected within 18 months before diagnosis 
      was 88%. The adjusted odds ratio (OR) of lung cancer for specimens collected 
      within 18 months before a cancer diagnosis was higher for the CA-FISH assay [OR, 
      29.9; 95% confidence interval (95% CI), 9.5-94.1] than for previously studied ORs 
      of cytologic atypia (OR, 1.8; 95% CI, 1.3-2.6) and gene promoter methylation (OR, 
      6.5; 95% CI, 1.2-35.5). Whether CA-FISH is an indicator of extreme risk for 
      incident lung cancer or detects exfoliated cancer cells is unknown. The apparent 
      promise of CA-FISH in sputum for assessing lung cancer risk and/or for lung 
      cancer early detection now needs to be validated in a clinical screening trial.
CI  - (c) 2010 AACR.
FAU - Varella-Garcia, Marileila
AU  - Varella-Garcia M
AD  - University of Colorado Denver, 12801 East 17th Avenue, Aurora, CO 80045, USA. 
      Marileila.Garcia@ucdenver.edu
FAU - Schulte, Aline P
AU  - Schulte AP
FAU - Wolf, Holly J
AU  - Wolf HJ
FAU - Feser, William J
AU  - Feser WJ
FAU - Zeng, Chan
AU  - Zeng C
FAU - Braudrick, Sarah
AU  - Braudrick S
FAU - Yin, Xiang
AU  - Yin X
FAU - Hirsch, Fred R
AU  - Hirsch FR
FAU - Kennedy, Timothy C
AU  - Kennedy TC
FAU - Keith, Robert L
AU  - Keith RL
FAU - Baron, Anna E
AU  - Baron AE
FAU - Belinsky, Steven A
AU  - Belinsky SA
FAU - Miller, York E
AU  - Miller YE
FAU - Byers, Tim
AU  - Byers T
FAU - Franklin, Wilbur A
AU  - Franklin WA
LA  - eng
GR  - P50CA58184/CA/NCI NIH HHS/United States
GR  - P50 CA058187/CA/NCI NIH HHS/United States
GR  - P30 CA046934-22S49003/CA/NCI NIH HHS/United States
GR  - P50 CA058184/CA/NCI NIH HHS/United States
GR  - P30 CA046934/CA/NCI NIH HHS/United States
GR  - P30 CA046934-22S59003/CA/NCI NIH HHS/United States
GR  - P30 CA046934-209003/CA/NCI NIH HHS/United States
GR  - P30 CA046934-22S39003/CA/NCI NIH HHS/United States
GR  - U01-CA85070/CA/NCI NIH HHS/United States
GR  - P30 CA046934-229003/CA/NCI NIH HHS/United States
GR  - U01 CA085070/CA/NCI NIH HHS/United States
GR  - P30-CA46934/CA/NCI NIH HHS/United States
GR  - P50CA58187/CA/NCI NIH HHS/United States
GR  - P30 CA046934-219003/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100323
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Biomarkers, Tumor)
SB  - IM
CIN - Cancer Prev Res (Phila). 2010 Apr;3(4):420-3. PMID: 20332300
CIN - Cancer Prev Res (Phila). 2010 Apr;3(4):416-9. PMID: 20332302
MH  - Aged
MH  - Area Under Curve
MH  - Biomarkers, Tumor/analysis/*genetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Incidence
MH  - Lung Neoplasms/*diagnosis/*epidemiology/genetics
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - ROC Curve
MH  - Sensitivity and Specificity
MH  - Sputum/*cytology
PMC - PMC2939746
MID - NIHMS157372
EDAT- 2010/03/25 06:00
MHDA- 2010/06/26 06:00
PMCR- 2011/04/01
CRDT- 2010/03/25 06:00
PHST- 2010/03/25 06:00 [entrez]
PHST- 2010/03/25 06:00 [pubmed]
PHST- 2010/06/26 06:00 [medline]
PHST- 2011/04/01 00:00 [pmc-release]
AID - 1940-6207.CAPR-09-0165 [pii]
AID - 10.1158/1940-6207.CAPR-09-0165 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2010 Apr;3(4):447-53. doi: 
      10.1158/1940-6207.CAPR-09-0165. Epub 2010 Mar 23.